Skip to main content
Innate Pharma S.A. (EPA:IPH)
France flag France · Delayed Price · Currency is EUR
1.390
+0.016 (1.16%)
Mar 6, 2026, 5:35 PM CET

Innate Pharma Revenue

Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.

Revenue (ttm)
12.64M
Revenue Growth
-62.60%
P/S Ratio
10.31
Revenue / Employee
72.62K
Employees
174
Market Cap
130.28M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202420.12M-41.52M-67.36%
Dec 31, 202361.64M3.97M6.88%
Dec 31, 202257.67M32.97M133.47%
Dec 31, 202124.70M-45.07M-64.60%
Dec 31, 202069.77M-15.68M-18.35%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Sensorion 5.65M
Adocia 12.88M
MaaT Pharma 3.92M
ABIONYX Pharma 4.33M
OSE Immunotherapeutics 1.78M
Transgene 7.58M
Valerio Therapeutics Société anonyme 1.83M
Cellectis 70.36M
Revenue Rankings

Innate Pharma News

More News